Mumbai, April 10 -- This drug is used to treat multiple cancers by inhibiting VEGF (vascular endothelial growth factor), effectively cutting off blood supply to tumors.

This marks Biocon's seventh biosimilar approval in the U.S., expanding its oncology arsenal alongside OGIVRI (trastuzumab) and FULPHILA (pegfilgrastim). JOBEVNE is already being sold in Europe and Canada under the name ABEVMY.

CEO Shreehas Tambe hailed the approval as a testament to Biocon's scientific strength and mission to make affordable biologics widely available. With U.S. sales of bevacizumab hitting

Published by HT Digital Content Services with permission from Capital Market....